{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:20:58Z","timestamp":1792423258747,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.euroneuro.2016.01.005","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T15:58:14Z","timestamp":1453478294000},"page":"756-766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A\/2A agonist ergotamine on psilocybin-induced psychedelic experience"],"prefix":"10.1016","volume":"26","author":[{"given":"Thomas","family":"Pokorny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin H.","family":"Preller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Kraehenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz X.","family":"Vollenweider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.euroneuro.2016.01.005_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/cercor\/bhg128","article-title":"Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex","volume":"14","author":"Amarg\u00f3s-Bosch","year":"2004","journal-title":"Cereb. Cortex"},{"issue":"2","key":"10.1016\/j.euroneuro.2016.01.005_bib2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0306-4522(91)90128-B","article-title":"5-Hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex","volume":"40","author":"Araneda","year":"1991","journal-title":"Neuroscience"},{"issue":"12","key":"10.1016\/j.euroneuro.2016.01.005_bib3","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1093\/cercor\/bht178","article-title":"Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A\/2A receptor agonist psilocybin","volume":"24","author":"Bernasconi","year":"2014","journal-title":"Cereb. Cortex"},{"issue":"24","key":"10.1016\/j.euroneuro.2016.01.005_bib4","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm000339w","article-title":"Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines","volume":"43","author":"Blair","year":"2000","journal-title":"J. Med. Chem."},{"issue":"3\u20134","key":"10.1016\/j.euroneuro.2016.01.005_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0028-3908(94)90059-0","article-title":"Molecular biology of 5-HT receptors","volume":"33","author":"Boess","year":"1994","journal-title":"Neuropharmacology"},{"issue":"4\u20135","key":"10.1016\/j.euroneuro.2016.01.005_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0028-3908(97)00049-X","article-title":"RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist","volume":"36","author":"Bonhaus","year":"1997","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.euroneuro.2016.01.005_bib7","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1517\/14656566.2014.918955","article-title":"Treating psychosis in movement disorder patients: a review","volume":"15","author":"Borek","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"issue":"10","key":"10.1016\/j.euroneuro.2016.01.005_bib8","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1162\/089892905774597191","article-title":"Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors","volume":"17","author":"Carter","year":"2005","journal-title":"J. Cognit. Neurosci."},{"issue":"3","key":"10.1016\/j.euroneuro.2016.01.005_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-007-0930-9","article-title":"Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans","volume":"195","author":"Carter","year":"2007","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.euroneuro.2016.01.005_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s002100000291","article-title":"In vivo actions of the selective 5-HT1A receptor agonist BAY\u00d73702 on serotonergic cell firing and release","volume":"362","author":"Casanovas","year":"2000","journal-title":"Naunyn Schmiedeberg\u05f3s Arch. Pharmacol."},{"issue":"9","key":"10.1016\/j.euroneuro.2016.01.005_bib11","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","article-title":"Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research","volume":"27","author":"Celada","year":"2013","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.euroneuro.2016.01.005_bib12","first-page":"252","article-title":"The therapeutic role of 5-HT1A and 5-HT2A receptors in depression","volume":"29","author":"Celada","year":"2004","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.euroneuro.2016.01.005_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnint.2013.00025","article-title":"Serotonin modulation of cortical neurons and networks","volume":"7","author":"Celada","year":"2013","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.euroneuro.2016.01.005_bib14","series-title":"The Corsini Encyclopedia of Psychology","article-title":"Symptom Checklist-90-Revised","author":"Derogatis","year":"2010"},{"issue":"4","key":"10.1016\/j.euroneuro.2016.01.005_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.euroneuro.2005.10.003","article-title":"Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by a 5-HT1A receptor agonist","volume":"16","author":"D\u00edaz-Mataix","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl 2","key":"10.1016\/j.euroneuro.2016.01.005_bib16","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2016.01.005_bib17","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1476-5381.1993.tb13727.x","article-title":"The effects of alpha 2-adrenoceptor antagonists on the inhibition of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced head shakes by 5-HT1A receptor agonists in the mouse","volume":"109","author":"Dursun","year":"1993","journal-title":"Br. J. Pharmacol."},{"issue":"3B","key":"10.1016\/j.euroneuro.2016.01.005_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-9343(86)90331-1","article-title":"Metabolism and disposition of buspirone","volume":"80","author":"Gammans","year":"1986","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.euroneuro.2016.01.005_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2016.01.005_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s002130051130","article-title":"Assessing prepulse inhibition of startle in wild-type and knockout mice","volume":"147","author":"Geyer","year":"1999","journal-title":"Psychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2016.01.005_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.euroneuro.2016.01.005_bib22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","article-title":"Serotonin research: contributions to understanding psychoses","volume":"29","author":"Geyer","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"issue":"7183","key":"10.1016\/j.euroneuro.2016.01.005_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonz\u00e1lez-Maeso","year":"2008","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.euroneuro.2016.01.005_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonz\u00e1lez-Maeso","year":"2007","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.euroneuro.2016.01.005_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2016.01.005_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00213-009-1718-x","article-title":"LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor","volume":"208","author":"Halberstadt","year":"2010","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.euroneuro.2016.01.005_bib27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00213-013-3006-z","article-title":"Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement","volume":"227","author":"Halberstadt","year":"2013","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.euroneuro.2016.01.005_bib28","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1177\/0269881110388326","article-title":"Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice","volume":"25","author":"Halberstadt","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2016.01.005_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1021\/cn300138m","article-title":"Animal models of serotonergic psychedelics","volume":"4","author":"Hanks","year":"2013","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.euroneuro.2016.01.005_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0031-6865(97)00014-9","article-title":"Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man","volume":"72","author":"Hasler","year":"1997","journal-title":"Pharm. Acta Helv."},{"issue":"2","key":"10.1016\/j.euroneuro.2016.01.005_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"issue":"3\u20134","key":"10.1016\/j.euroneuro.2016.01.005_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0014-2999(82)90265-5","article-title":"Buspirone: effects on central monoaminergic transmission--possible relevance to animal experimental and clinical findings","volume":"83","author":"Hjorth","year":"1982","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2016.01.005_bib33","series-title":"Chemical constitution and pharmacodynamic actions","first-page":"169","article-title":"Psychotomimetic agents","author":"Hofmann","year":"1968"},{"issue":"2","key":"10.1016\/j.euroneuro.2016.01.005_bib34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00210-004-0951-4","article-title":"Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors","volume":"370","author":"Knight","year":"2004","journal-title":"Naunyn Schmiedeberg\u05f3s Arch. Pharmacol."},{"issue":"5","key":"10.1016\/j.euroneuro.2016.01.005_bib35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.biopsych.2010.10.002","article-title":"The 5-HT2A\/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations","volume":"69","author":"Kometer","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"19","key":"10.1016\/j.euroneuro.2016.01.005_bib36","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1007\/s00213-015-4026-7","article-title":"Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations","volume":"232","author":"Kometer","year":"2015","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.euroneuro.2016.01.005_bib37","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","article-title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors","volume":"72","author":"Kometer","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"25","key":"10.1016\/j.euroneuro.2016.01.005_bib38","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","article-title":"Activation of serotonin 2A receptors underlies the psilocybin-induced effects on \u03b1 oscillations, N170 visual-evoked potentials, and visual hallucinations","volume":"33","author":"Kometer","year":"2013","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.euroneuro.2016.01.005_bib39","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","article-title":"Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers","volume":"78","author":"Kraehenmann","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.01.005_bib40","article-title":"The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity","author":"Kraehenmann","year":"2015","journal-title":"Neuroimage Clin."},{"issue":"3\u20134","key":"10.1016\/j.euroneuro.2016.01.005_bib41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/BF02245219","article-title":"Cross-tolerance studies of serotonin receptors involved in behavioral effects of LSD in rats","volume":"113","author":"Krebs","year":"1994","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.euroneuro.2016.01.005_bib42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s002130050740","article-title":"Evidence for a functional interaction between 5-HT1A and 5-HT2 receptors in rats","volume":"140","author":"Krebs-Thomson","year":"1998","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.euroneuro.2016.01.005_bib43","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1002\/hbm.22833","article-title":"Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin","volume":"36","author":"Lebedev","year":"2015","journal-title":"Hum. Brain Mapp."},{"issue":"1","key":"10.1016\/j.euroneuro.2016.01.005_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cne.902800104","article-title":"Quantitative autoradiographic mapping of serotonin 5-HT1 and 5-HT2 receptors and uptake sites in the neocortex of the rhesus monkey","volume":"280","author":"Lidow","year":"1989","journal-title":"J. Comp. Neurol."},{"issue":"8","key":"10.1016\/j.euroneuro.2016.01.005_bib45","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1476-5381.2010.00738.x","article-title":"Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors","volume":"160","author":"Llad\u00f3-Pelfort","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.euroneuro.2016.01.005_bib46","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/cercor\/bhr220","article-title":"5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons","volume":"22","author":"Llad\u00f3-Pelfort","year":"2012","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.euroneuro.2016.01.005_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","article-title":"Buspirone: what is it all about?","volume":"1461","author":"Loane","year":"2012","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.euroneuro.2016.01.005_bib48","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00003088-199936040-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug","volume":"36","author":"Mahmood","year":"1999","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.euroneuro.2016.01.005_bib49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0269881114568040","article-title":"Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?","volume":"29","author":"Maji\u0107","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.01.005_bib50","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/BF00413052","article-title":"\u00dcber den Einfluss von Ergotamin auf die LSD-\"Psychose\" beim Menschen","volume":"5","author":"Matussek","year":"1964","journal-title":"Psychopharmacologia"},{"issue":"2","key":"10.1016\/j.euroneuro.2016.01.005_bib51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3233\/JPD-130300","article-title":"Changes in 5-HT2A receptor expression in untreated, de novo patients with Parkinson\u05f3s disease","volume":"4","author":"Melse","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.euroneuro.2016.01.005_bib52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","article-title":"In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems","volume":"172","author":"Meltzer","year":"2008","journal-title":"Prog. Brain Res."},{"issue":"4","key":"10.1016\/j.euroneuro.2016.01.005_bib53","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson\u05f3s disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2016.01.005_bib54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-642-25761-2_4","article-title":"Serotonergic mechanisms as targets for existing and novel antipsychotics","volume":"212","author":"Meltzer","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2016.01.005_bib55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.euroneuro.2016.01.005_bib56","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0924-9338(15)30017-1","article-title":"The effect of 5-HT2A\/1A agonist treatment on social cognition, empathy, and social decision-making","volume":"30","author":"Preller","year":"2015","journal-title":"Eur. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2016.01.005_bib57","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0014-2999(98)00361-6","article-title":"Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone","volume":"352","author":"Protais","year":"1998","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2016.01.005_bib58","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1523\/JNEUROSCI.3335-09.2010","article-title":"Serotonin modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 5-HT1A and 5-HT2A receptors","volume":"30","author":"Puig","year":"2010","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.euroneuro.2016.01.005_bib59","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/npp.2011.228","article-title":"Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers","volume":"37","author":"Quednow","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.euroneuro.2016.01.005_bib60","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1017\/S1461145714000261","article-title":"The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs","volume":"17","author":"Riga","year":"2014","journal-title":"Int. J. Neuropsychopharmacol"},{"issue":"10","key":"10.1016\/j.euroneuro.2016.01.005_bib61","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb. Cortex"},{"issue":"6","key":"10.1016\/j.euroneuro.2016.01.005_bib62","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00726-011-1078-9","article-title":"Serotonin and molecular neuroimaging in humans using PET","volume":"42","author":"Saulin","year":"2012","journal-title":"Amino Acids"},{"issue":"1","key":"10.1016\/j.euroneuro.2016.01.005_bib63","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00213-012-2811-0","article-title":"The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions","volume":"225","author":"Schmidt","year":"2013","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.euroneuro.2016.01.005_bib64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)09485-6","article-title":"1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A\/2C antagonists, D1 antagonists and 5-HT1A agonists","volume":"273","author":"Schreiber","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl 20","key":"10.1016\/j.euroneuro.2016.01.005_bib65","first-page":"S22","article-title":"The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2016.01.005_bib66","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1526-4610.2003.03034.x","article-title":"Ergotamine and dihydroergotamine: history, pharmacology, and efficacy","volume":"43","author":"Silberstein","year":"2003","journal-title":"Headache"},{"issue":"1\u20132","key":"10.1016\/j.euroneuro.2016.01.005_bib67","first-page":"121","article-title":"Human psychopharmacology of N, N-dimethyltryptamine","volume":"73","author":"Strassman","year":"1996","journal-title":"Behav. Brain Res."},{"issue":"11","key":"10.1016\/j.euroneuro.2016.01.005_bib68","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2016.01.005_bib69","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archpsyc.59.6.514","article-title":"Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635","volume":"59","author":"Tauscher","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2016.01.005_bib70","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2125.1982.tb01366.x","article-title":"Bioavailability of sublingual ergotamine","volume":"13","author":"Tfelt-Hansen","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"Pt 1","key":"10.1016\/j.euroneuro.2016.01.005_bib71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/brain\/123.1.9","article-title":"Ergotamine in the acute treatment of migraine: a review and European consensus","volume":"123","author":"Tfelt-Hansen","year":"2000","journal-title":"Brain"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2016.01.005_bib72","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1185\/0300799039117009","article-title":"Ergotamine, dihydroergotamine: current uses and problems","volume":"17","author":"Tfelt-Hansen","year":"2001","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.euroneuro.2016.01.005_bib73","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.npp.1300005","article-title":"Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia","volume":"28","author":"Umbricht","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.euroneuro.2016.01.005_bib74","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/sj.npp.1301324","article-title":"The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval","volume":"32","author":"Vollenweider","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.euroneuro.2016.01.005_bib75","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0361-9230(01)00646-3","article-title":"A systems model of altered consciousness: integrating natural and drug-induced psychoses","volume":"56","author":"Vollenweider","year":"2001","journal-title":"Brain Res. Bull."},{"issue":"9","key":"10.1016\/j.euroneuro.2016.01.005_bib76","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"issue":"17","key":"10.1016\/j.euroneuro.2016.01.005_bib77","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"issue":"4","key":"10.1016\/j.euroneuro.2016.01.005_bib78","doi-asserted-by":"crossref","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","article-title":"Brain mechanisms of hallucinogens and entactogens","volume":"3","author":"Vollenweider","year":"2001","journal-title":"Dialogues Clin. Neurosci."},{"issue":"8","key":"10.1016\/j.euroneuro.2016.01.005_bib79","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/cercor\/bhn219","article-title":"Enriched expression of serotonin 1B and 2A receptor genes in macaque visual cortex and their bidirectional modulatory effects on neuronal responses","volume":"19","author":"Watakabe","year":"2009","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.euroneuro.2016.01.005_bib80","unstructured":"In: Wittchen, H.-U. (Ed.), 1997. DIA-X. Swets Test Services. Frankfurt."},{"issue":"5","key":"10.1016\/j.euroneuro.2016.01.005_bib81","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.biopsych.2003.11.016","article-title":"Decreased 5-HT1A receptor binding in amygdala of schizophrenia","volume":"55","author":"Yasuno","year":"2004","journal-title":"Biol. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16000158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16000158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T02:27:51Z","timestamp":1748744871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X16000158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0924977X16000158"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.01.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A\/2A agonist ergotamine on psilocybin-induced psychedelic experience","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}